Showing 6461-6470 of 7650 results for "".
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- Study: Fine Water Particle Sprays Improve Facial Skin Moisture for Hourshttps://practicaldermatology.com/news/study-fine-water-particle-sprays-improve-facial-skin-moisture-for-hours/2457515/Spraying fine water particles onto the face in winter, when skin is dry, improved skin hydration and softening, according to a new study in Skin Research & Technology. In addition, water retention remained co
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month/2457519/November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society (IHhS) wants the world to know that hyperhidrosis’ (Hh) uncontrollable, no-fault sweating can soak through clothing and water-damage electronics. This makes
- Mayne Pharma Acquires FDA-approved Halobetasol Foamhttps://practicaldermatology.com/news/mayne-pharma-acquires-fda-approved-halobetasol-foam/2457520/Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for an investment of up to $32 million (comprising $10 million in cash up front, $5 million at commercial launch plus continge
- Endocannabinoids Effective in Lupus Modelhttps://practicaldermatology.com/news/endocannabinoids-effective-in-lupus-model/2457521/Zylö Therapeutics’ patented Nanopod™ aerogel delivery technology was used to demonstrate the efficacy of endocannabinoids in a model of cutaneous lupus in a study presented last month at the meeting of the American College of Rheumatology. There is growing evidence that t
- AAD Releases New Melanoma Guidelineshttps://practicaldermatology.com/news/aad-releases-new-melanoma-guidelines/2457522/As National Healthy Skin Month begins, the American Academy of Dermatology’s (AAD) new melanoma guidelines shed light on risk of melanoma prognosis during pregnancy, the role of formal genetic testing in at-risk families and other aspects of care for primary cutaneous melanoma.
- New AD Estimate: As Many As 16.5 Million Adults Have ADhttps://practicaldermatology.com/news/new-ad-estimate-as-many-as-165-million-adults-have-ad/2457524/As many as 16.5 million adults in America have atopic dermatitis (AD). This estimate comes from a new study from the Perelman School of Medicine at the University of Pennsylvania, which also projected 6.6 million of these adults have disease that wo
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab